Healio  |  April 3, 2019

Regina LaBelle, JD, program director for the Addiction and Public Policy Initiative at the O’Neill Institute for National and Global Health Law at Georgetown University, suggested another reason.

“The settlement may also have been prompted by the company needing fewer distractions as it reviews its strategy of blaming illicit fentanyl instead of Oxycontin for the opioid epidemic,” she said. “This strategy may be the company’s only hope of legal victory.”

Read the article here.